Arcus Biosciences CEO reports transfer of 2,400 common shares

Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director.

Accepted by SEC EDGAR 01/02/2026 - 04:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director. On 12/30/2025, the reporting person transferred 2,400 shares of common stock at a reported price of $0, using transaction code G. After this transaction, the individual directly beneficially owns 2,192,409 shares of Arcus common stock.

According to the notes, the 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, while retaining voting and dispositive power over all of the transferred shares.

Insider Trade Summary

2,400 shares gifted

Gift 1 txn

Insider ROSEN TERRY J

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	2,400	$0.00	$0.00

Holdings After Transaction: Common Stock — 2,192,409 shares (Direct)

Footnotes (1)

1. F1. 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcus Biosciences (RCUS) report in this Form 4?

The filing reports that the Chief Executive Officer and director of Arcus Biosciences, Inc. transferred 2,400 shares of Arcus common stock on 12/30/2025, shown with transaction code G at a reported price of $0.

How many Arcus Biosciences (RCUS) shares does the insider own after the transaction?

Following the reported transaction, the insider directly beneficially owns 2,192,409 shares of Arcus Biosciences common stock.

Who is the reporting person in this Arcus Biosciences (RCUS) Form 4?

The reporting person is both a director and an officer of Arcus Biosciences, serving as Chief Executive Officer.

To whom were the 2,400 Arcus Biosciences (RCUS) shares transferred?

The 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the transferred shares.

Does the reporting person retain control over the transferred Arcus Biosciences (RCUS) shares?

Yes. The explanation states that the reporting person retains voting and dispositive power over all of the shares transferred to each family trust.

Is this Arcus Biosciences (RCUS) Form 4 filed by more than one reporting person?

No. The filing indicates that it is a Form filed by one reporting person, not by more than one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSEN TERRY J

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/30/2025		G(1)		2,400	D	$0	2,192,409	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust.

	/s/ Carolyn Tang, Attorney-in-Fact	01/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.